News and Events

Adimab will deliver a keynote on developability profiling, off-target screening, and CDR engineering, present on TCR-targeting VHH bispecifics as an NHP cross-reactive alternative to CD3 T cell engagers, and chair a session on de novo design and library-based peptide discovery. Two posters will also be presented.